Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment

Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment

Background: Postoperative treatment of patients with either BRAF/MEK inhibitors or anti-PD1 antibodies in the adjuvant setting results in improved recurrence free survival and has therefore become a standard of care for most patients with resected stage III melanoma. For patients who need systemic t...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Weichenthal, Inge Marie Svane, Johanna Mangana, Ulrike Leiter, Friedegund Meier, Christina Ruhlmann, Dimitrios Ziogas, Reinhard Dummer, Pablo Cerenzuela, Jose Luis Manzano, Marc Bender, Shan Jiang, Paolo Antonio Ascierto, Iva Gavrilova, Lidija Kandolf, Helen Gogas, Peter Mohr, Dirk Schadendorf, Eva Ellebaek
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:EJC Skin Cancer
Subjects:
Melanoma
Immunotherapy
Adjuvant treatment
Skin Cancer
Immune Checkpoint Inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2772611824002593
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2772611824002593

Similar Items